Drug Trial Radar · NCT06006559
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Feb 20, 2024
Primary completion
Jul 22, 2027
Study completion Jul 30, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Conditions
- Dengue
Interventions
EYU688Drug
EYU688 administered by oral route
PlaceboDrug
Matching placebo administered orally as capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment startTime frame: From predose to 48 hours post treatment start
Locations
27 sites in 7 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Manaus, Amazonas, Brazil · Recruiting
Novartis Investigative Site
Brasília, Federal District, Brazil · Recruiting
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Novartis Investigative Site
São Caetano do Sul, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São José do Rio Preto, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Sorocaba, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Barranquilla, Atlántico, Colombia · Recruiting
Novartis Investigative Site
Bucaramanga, Santander Department, Colombia · Recruiting
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia · Recruiting
Novartis Investigative Site
Belagavi, Karnataka, India · Recruiting
Novartis Investigative Site
Mumbai, Maharashtra, India · Withdrawn
Novartis Investigative Site
Pune, Maharashtra, India · Recruiting
Novartis Investigative Site
Jaipur, Rajasthan, India · Recruiting
Novartis Investigative Site
Chennai, Tamil Nadu, India · Recruiting
Novartis Investigative Site
Kuala Selangor, Malaysia · Recruiting
Novartis Investigative Site
Kuantan, Pahang, Malaysia · Recruiting
Novartis Investigative Site
Ipoh, Perak, Malaysia · Recruiting
Novartis Investigative Site
Seberang Jaya, Pulau Pinang, Malaysia · Recruiting
Novartis Investigative Site
Miri, Sarawak, Malaysia · Recruiting
Novartis Investigative Site
Oaxaca City, Mexico · Recruiting
Novartis Investigative Site
Veracruz, Mexico · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Singapore, Singapore, Singapore · Recruiting
Novartis Investigative Site
Haiphong, Vietnam · Recruiting
Novartis Investigative Site
Hanoi, Vietnam · Recruiting
Novartis Investigative Site
Ho Chi Minh City, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.